These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33535836)

  • 21. [Treatment Options in Non-alcoholic Fatty Liver Disease].
    Kim W
    Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.
    Henriksson E; Andersen B
    Front Endocrinol (Lausanne); 2020; 11():601349. PubMed ID: 33414764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.
    Schumacher JD; Guo GL
    Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials.
    Aggarwal P; Noureddin M; Harrison S; Jeannin S; Alkhouri N
    Expert Opin Investig Drugs; 2022 Feb; 31(2):163-172. PubMed ID: 35060815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
    Tacke F; Puengel T; Loomba R; Friedman SL
    J Hepatol; 2023 Aug; 79(2):552-566. PubMed ID: 37061196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Rotman Y; Sanyal AJ
    Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and opportunities in NASH drug development.
    Harrison SA; Allen AM; Dubourg J; Noureddin M; Alkhouri N
    Nat Med; 2023 Mar; 29(3):562-573. PubMed ID: 36894650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.
    Alkhouri N
    Expert Opin Investig Drugs; 2020 Feb; 29(2):115-116. PubMed ID: 31971024
    [No Abstract]   [Full Text] [Related]  

  • 30. [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?].
    Huber Y; Galle PR; Schattenberg JM
    Z Gastroenterol; 2020 Jan; 58(1):68-73. PubMed ID: 31931543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
    Ogawa Y; Yoneda M; Kobayashi T; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A
    Expert Opin Pharmacother; 2019 Jan; 20(1):69-82. PubMed ID: 30411635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586
    [No Abstract]   [Full Text] [Related]  

  • 34. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
    Hye Khan MA; Schmidt J; Stavniichuk A; Imig JD; Merk D
    Biochem Pharmacol; 2019 Aug; 166():212-221. PubMed ID: 31129048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging and future therapies for nonalcoholic steatohepatitis in adults.
    Mintziori G; Polyzos SA
    Expert Opin Pharmacother; 2016 Oct; 17(14):1937-46. PubMed ID: 27564402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

  • 39. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.
    Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW
    Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.